Alnylam Pharmaceuticals (ALNY)
Nasdaq Market Closed
Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on RNA interference, or RNAi, a biological process that can reduce the activity of specific genes by targeting messenger RNA. The company applies this mechanism to develop medicines for diseases in which silencing a disease-related gene may alter the course of illness. Its work places it among the best-known developers of RNAi therapeutics, with a platform designed to identify genetic targets, create RNA-based drug candidates, and deliver them to relevant tissues, particularly the liver.
Alnylam has built a commercial portfolio around rare and specialty diseases. Its marketed products include Onpattro and Amvuttra for hereditary transthyretin-mediated amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1. These medicines reflect the company’s strategy of addressing serious conditions with clearly defined molecular drivers and limited treatment options. Alnylam also benefits from partnered products, including Leqvio for cholesterol management, commercialized by Novartis, and Qfitlia for hemophilia A or B, commercialized by Sanofi.
Beyond its approved therapies, Alnylam maintains a pipeline across cardio-metabolic disease, hematology, neuroscience, and other areas where gene silencing may have clinical value. Investors typically view the company through the lens of its RNAi platform, commercial execution, regulatory milestones, and the potential for pipeline expansion into larger markets. As with many biotechnology businesses, its valuation can be sensitive to clinical trial results, reimbursement trends, product uptake, and competition from other genetic medicine technologies.
Last updated
- Market Cap
- $36,284,711,964
- P/E
- 62.86
- P/FCF
- 56.58
- P/S
- 8.46
- Enterprise Value
- $35,583,304,964
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- 675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200
The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea
Morgan Stanley Raises its Price Target on Alnylam (ALNY)
Panic grips Ionis Pharmaceuticals investors amid bad news spree
Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?
Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)?
Alnylam (ALNY) Gets An Opening In ATTR CM As Rival Trial Fails
Alnylam Pharmaceuticals (ALNY) Stock Looks Rich On Earnings Yet Strong On Returns
US Stock Market Today: S&P 500 Futures Edge Higher On Persistent Higher Yield Concerns
Strength in Chipmakers Boosts Stock Indexes
Stocks Climb on Strength in Chipmakers
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical
Backdoor AI Beneficiary Yields 8.8%, Trades at 13% Discount
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
BlackRock Fund Dividend Reset Offers 9.2% Yield at a Discount
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
Scenic Enters License and Research Agreement with Alnylam
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $36,284,711,964
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $35,583,304,964
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 62.86
- P/B
P/B ratio compares a company's share price to its book value per share.
- 33.74
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 8.46
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 44.1
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 8.3
- EPS
- 4.32
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 56.58
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 50.9
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- $641,338,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 53.68%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 11.25%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.94
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 3.13
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 3.06
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.27
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $1,483,287
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 271.77
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 1.17B | 1.1B | 1.25B | 773.69M | 594.19M |
| Cost of revenue | 207.52M | 267.72M | 197.23M | 142.03M | 70.18M |
| Gross profit | 959.66M | 829.31M | 1.05B | 631.66M | 524.01M |
| Operating income | 268.64M | 131.72M | 367.98M | -16.2M | 18.08M |
| EBITDA | 282.19M | 145.22M | 381.79M | -2.26M | 32.48M |
| Net income | 205.99M | 186.42M | 251.08M | -66.28M | -18.25M |
| Income taxes | 15.66M | -25.28M | -12.12M | 30.92M | 15.88M |
| Interest expense | -69.29M | -129.34M | -44.4M | -40.25M | -58.31M |
| Other operating expenses | 3.6M | 0 | 2.92M | 924K | 858K |
| Total operating expenses | 691.02M | 697.59M | 683.81M | 647.86M | 505.93M |
| Basic EPS | 1.55 | 1.41 | 1.91 | -0.51 | -0.14 |
| Diluted EPS | 1.51 | 1.38 | 1.84 | -0.51 | -0.14 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 5.13B | 4.97B | 4.85B | 4.57B | 4.21B |
| Total liabilities | 4.05B | 4.18B | 4.62B | 4.32B | 4.1B |
| Total equity | 1.08B | 789.18M | 233.89M | 250.59M | 115.44M |
| Cash & equivalents | 1.71B | 1.66B | 1.49B | 1.11B | 1.02B |
| Current assets | 4.22B | 4.05B | 3.95B | 3.64B | 3.27B |
| Current liabilities | 1.35B | 1.47B | 1.56B | 1.3B | 1.08B |
| Accounts payable | 126.63M | 115.72M | 117.59M | 102.39M | 97.4M |
| Receivables | 883.96M | 777.57M | 964.77M | 567.11M | 418.04M |
| Inventories | 84.03M | 82.72M | 75.38M | 71.69M | 65.58M |
| Long-term debt | 1.01B | 1.01B | 1.04B | 1.03B | 1.03B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 70.5M | 163.56M | 325.11M | 153.73M | -120.31M |
| Investing cash flow | -25.54M | -37.17M | 501.11M | -141.38M | 113.77M |
| Financing cash flow | 15.71M | 45.32M | -448.35M | 53.76M | 46.08M |
| Change in cash | 53.61M | 166.01M | 376.94M | 93.61M | 53.6M |
| Net income | 205.99M | 186.42M | 251.08M | -66.28M | -18.25M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 3 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 144 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| form 4 | Form 4 — Cravatt Benjamin | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| edgar index | 8-K — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| form 4 | Form 4 — Arbuckle Stuart A | View Filing | |
| form 4 | Form 4 — Arbuckle Stuart A | View Filing | |
| form 4 | Form 4 — Ausiello Dennis A | View Filing | |
| form 4 | Form 4 — Ausiello Dennis A | View Filing | |
| form 4 | Form 4 — Ausiello Dennis A | View Filing | |
| form 4 | Form 4 — BRANDICOURT OLIVIER | View Filing | |
| form 4 | Form 4 — BRANDICOURT OLIVIER | View Filing | |
| form 4 | Form 4 — HAMBURG MARGARET A | View Filing | |
| form 4 | Form 4 — HAMBURG MARGARET A | View Filing | |
| form 4 | Form 4 — KELLOGG PETER N | View Filing | |
| form 4 | Form 4 — KELLOGG PETER N | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| form 4 | Form 4 — PYOTT DAVID E I | View Filing | |
| form 4 | Form 4 — Reitan Colleen F | View Filing | |
| form 4 | Form 4 — Reitan Colleen F | View Filing | |
| form 4 | Form 4 — SCHULMAN AMY W | View Filing | |
| form 4 | Form 4 — SCHULMAN AMY W | View Filing | |
| form 4 | Form 4 — Sigal Charles Elliott | View Filing | |
| form 4 | Form 4 — Sigal Charles Elliott | View Filing | |
| form 4 | Form 4 — Sigal Charles Elliott | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | SCHEDULE 13G/A — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | SCHEDULE 13G/A — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| form 4 | Form 4 — SCHULMAN AMY W | View Filing | |
| form 4 | Form 4 — SCHULMAN AMY W | View Filing | |
| edgar index | SCHEDULE 13G/A — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 8-K — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 10-Q — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 3 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 4 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| form 3 | Form 3 — McLaughlin Melissa | View Filing | |
| form 3 | Form 3 — McLaughlin Melissa | View Filing | |
| edgar index | ARS — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | DEF 14A — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | DEFA14A — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| edgar index | 144 — ALNYLAM PHARMACEUTICALS, INC. | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing | |
| form 4 | Form 4 — McLaughlin Melissa | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free